All In Biotech

Drug Trial Radar · NCT05798923

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Aug 30, 2023

Primary completion

Mar 2028

Study completion Feb 2029

Sponsor

Lead sponsor
IRulya Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Apr 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).

Conditions

  • Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Interventions

  • PlaceboDrug

    Matching placebo administered via dry powder inhalation

  • LAM-001Drug

    LAM-001 administered via dry powder inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the change in PVR at 24 weeksTime frame: 24 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona · Recruiting

  • Yale New Haven Hospital

    New Haven, Connecticut · Active not recruiting

  • Brigham & Women's Hospital

    Boston, Massachusetts · Not yet recruiting

  • Temple Lung Center, Temple University

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.